摘要
多发性骨髓瘤是恶性克隆性浆细胞疾病,骨髓瘤骨病是其重要的临床表现之一.多年来,对骨髓瘤骨病的溶骨性病变机制的研究主要集中在破骨细胞数量和活性的增加.近些年来的研究发现,成骨细胞数量和活性的减低也参与了溶骨性病变的发生和发展,对骨髓瘤骨病病理生理机制的研究促进了新的靶向性药物研发.
Multiple myeloma is a plasma cell malignancy and bone disease is one of the important clinical features.For decades,the study on the mechanism of myeloma osteolytic disease mainly focused on the enhanced osteoclasts recruitment and activity.Recently,decreased osteoblasts number and activity were also found to be involved in the pathogenesis of myeloma bone disease.The progress in acknowledge of the pathophysiology of myeloma bone disease leaded to identify new therapeutic targets.
出处
《北华大学学报（自然科学版）》
CAS
2009年第6期507-512,共6页
Journal of Beihua University（Natural Science）
关键词
多发性骨髓瘤骨病
机制
治疗
Multiple myeloma bone disease
Mechanism
Treatment
